Oxaliplatin
别名: L-OHP,NSC 266046
中文名称:奥沙利铂
目录号:S1224 Purity: 99.76%
铂类药物不建议使用DMSO溶解,易失活!
Oxaliplatin是一种DNA烷基化药物可以激活自噬。Oxaliplatin在RT4,TCCSUP,A2780,HT-29,U-373MG,U-87MG,SK-MEL-2,和 HT-144细胞中通过形成DNA加合物而抑制DNA合成。在溶液中不稳定,请现配现用!铂类药物不建议用DMSO溶解,易失活!
CAS: 61825-94-3
客户使用Selleck的Oxaliplatin发表文献245篇
- Mol Cancer, 2024 23(1):186
- Mol Cancer, 2024 23(1):23
- Gastroenterology, 2024 S0016-5085(24)00062-3
- Drug Resist Updat, 2023 71:101005
- Nat Cancer, 2023 4(9):1362-1381
- Cancer Cell, 2022 40(10):1207-1222.e10
- Signal Transduct Target Ther, 2022 7(1):87
- Cancer Discov, 2022 candisc.1117.2021
- Cell, 2021 184(25):6119-6137.e26
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Mol Cancer, 2021 20(1):10
- Nat Microbiol, 2021 10.1038/s41564-020-00831-6
- Cancer Cell, 2020 37(3):371-386
- Cell Discov, 2020 21;6:21
- J Hematol Oncol, 2020 1;13(1):40
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Nat Med, 2018 24(7):954-960
- Cancer Cell, 2018 33(6):1094-1110
- Cell, 2017 170(3):548-563
- Gastroenterology, 2017 153(4):1082-1095
- Exp Cell Res, 2025 444(1):114344
- Nat Commun, 2024 15(1):2503
- Cell Rep Med, 2024 5(7):101627
- Cell Rep Med, 2024 5(10):101778
- Redox Biol, 2024 76:103349
- J Exp Clin Cancer Res, 2024 43(1):235
- J Immunother Cancer, 2024 12(7)e008888
- J Adv Res, 2024 S2090-1232(24)00413-2
- Cell Death Dis, 2024 15(3):187
- Cell Rep, 2024 43(4):114044
- Cell Mol Life Sci, 2024 81(1):452
- NPJ Precis Oncol, 2024 8(1):52
- J Transl Med, 2024 22(1):133
- J Transl Med, 2024 22(1):1130
- Front Immunol, 2024 15:1458270
- mSystems, 2024 9(4):e0132323
- Cancer Cell Int, 2024 24(1):90
- iScience, 2024 27(1):108667
- Cancer Cell Int, 2024 24(1):29
- iScience, 2024 27(3):109247
- Neoplasia, 2024 56:101033
- BMC Cancer, 2024 24(1):357
- PLoS One, 2024 19(8):e0308872
- BMC Pharmacol Toxicol, 2024 25(1):25
- Oncol Lett, 2024 27(1):33
- STAR Protoc, 2024 5(2):103090
- World J Oncol, 2024 15(2):169-180
- Cell Genom, 2024 4(5):100550
- Nat Commun, 2023 14(1):6505
- J Clin Invest, 2023 133(3)e158705
- Acta Pharm Sin B, 2023 13(11):4621-4637
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101277
- EMBO Mol Med, 2023 e16863.
- PLoS Biol, 2023 21(9):e3002256
- Int J Biol Sci, 2023 19(11):3526-3543
- Cell Rep, 2023 42(7):112778
- Cell Rep, 2023 42(4):112324
- Cell Commun Signal, 2023 21(1):9
- Elife, 2023 12e83867
- Biomed Pharmacother, 2023 162:114679
- Chin Med J (Engl), 2023 10.1097/CM9.0000000000002869
- iScience, 2023 26(8):107369
- Cancer Cell Int, 2023 23(1):63
- Front Pharmacol, 2023 14:1189245
- Int J Mol Sci, 2023 10.3390/ijms241915020
- iScience, 2023 26(7):107116
- Int J Oncol, 2023 62(4)45
- Cancers (Basel), 2023 15(23)5531
- Transl Oncol, 2023 27:101598
- Pharmaceuticals (Basel), 2023 16(5)757
- World J Gastroenterol, 2023 29(39):5452-5470
- Oncol Rep, 2023 50(3)170
- ACS Omega, 2023 8(18):15968-15978
- J Hepatocell Carcinoma, 2023 10:483-495
- Pharmgenomics Pers Med, 2023 16:229-238
- Mol Biol Cell, 2023 34(5):ar47
- Open Med (Wars), 2023 18(1):20230690
- Nan Fang Yi Ke Da Xue Xue Bao, 2023 10.12122/j.issn.1673-4254.2023.10.02
- Adv Sci (Weinh), 2022 e2201539
- Nat Protoc, 2022 10.1038/s41596-022-00740-4
- Theranostics, 2022 12(9):4386-4398
- Mol Ther, 2022 S1525-0016(22)00671-2
- Mol Ther, 2022 S1525-0016(22)00717-1
- Clin Cancer Res, 2022 28(17):3874-3889
- Redox Biol, 2022 55:102418
- J Exp Clin Cancer Res, 2022 41(1):5
- Cancer Res, 2022 82(20):3785-3801
- Clin Transl Med, 2022 12(2):e747
- Clin Transl Med, 2022 12(10):e1088
- ACS Appl Mater Interfaces, 2022 14(28):31625-31633
- Cell Death Dis, 2022 13(6):521
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-00927-1
- JCI Insight, 2022 7(22e158060)
- Cell Mol Life Sci, 2022 79(3):135
- Oncogene, 2022 10.1038/s41388-022-02253-6
- Front Immunol, 2022 13:1040256
- Front Immunol, 2022 13:837262
- Cell Death Discov, 2022 8(1):235
- iScience, 2022 25(10):105182
- Biomolecules, 2022 12(9)1256
- Oncotarget, 2022 13:1094-1108
- Am J Cancer Res, 2022 12(3):1393-1408
- Ann Clin Transl Neurol, 2022 10.1002/acn3.51691
- Cancers (Basel), 2022 14(3)821
- Cancers -Basel, 2022 14-174083
- Cancers (Basel), 2022 14(8)1968
- Cancers (Basel), 2022 14(5)1230
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:881487
- Front Oncol, 2022 12:877194
- Pharmaceuticals (Basel, 2022 15(91139)
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Clin Exp Metastasis, 2022 10.1007/s10585-021-10143-6
- J Proteomics, 2022 266:104682
- Exp Ther Med, 2022 24(3):586
- Acta Histochem, 2022 124(4):151895
- Anticancer Drugs, 2022 10.1097/CAD.0000000000001344
- Nat Commun, 2021 12(1):4840
- Adv Sci (Weinh), 2021 e2103360
- Autophagy, 2021 10.1080/15548627.2021.2008692
- Cell Death Differ, 2021 10.1038/s41418-020-00733-4
- Pharmacol Res, 2021 172:105815
- Pharmacol Res, 2021 S1043-6618(21)00453-9
- Int J Biol Sci, 2021 17(11):2756-2769
- Gigascience, 2021 10(4)giab026
- Cell Death Dis, 2021 12(5):449
- Cell Death Dis, 2021 12(4):337
- J Cachexia Sarcopenia Muscle, 2021 10.1002/jcsm.12703
- Cell Prolif, 2021 e13031
- Arch Toxicol, 2021 10.1007/s00204-021-03119-8
- iScience, 2021 24(11):103349
- Cancer Cell Int, 2021 21(1):709
- Front Pharmacol, 2021 12:689767
- Front Cell Dev Biol, 2021 9:719192
- Cancers (Basel), 2021 13(11)2539
- Cancers (Basel), 2021 13(5)
- Cancers (Basel), 2021 13(5)957
- Aging (Albany NY), 2021 13(6):8880-8894
- Front Mol Biosci, 2021 8:646542
- J Neurochem, 2021 156(5):642-657
- Front Oncol, 2021 11:667689
- Ann Transl Med, 2021 9(16):1317
- Molecules, 2021 26(19)5858
- Environ Toxicol, 2021 10.1002/tox.23355
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Biomed Res Int, 2021 2021:9986376
- Biochem Biophys Res Commun, 2021 544:65-72
- Biochem Biophys Res Commun, 2021 576:33-39
- Genet Test Mol Biomarkers, 2021 25(4):284-292
- Adv Biol Regul, 2021 S2212-4926(20)30091-9
- STAR Protoc, 2021 2(2):100574
- ACS Nano, 2020 28;14(4):5075-5089
- Cell Rep Med, 2020 1(9):100160
- Theranostics, 2020 10(5):1981-1996
- Cancer Res, 2020 80(21):4815-4827
- J Control Release, 2020 319:213-221
- Acta Biomater, 2020 S1742-7061(20)30751-0
- Cancer Lett, 2020 28;476:67-74
- Cancer Lett, 2020 473:74-89
- Cell Death Dis, 2020 11(10):822
- Oncogene, 2020 39(5):987-1003
- Int J Cancer, 2020 10.1002/ijc.33202
- Cells, 2020 9(6):E1474
- Cells, 2020 9(9)E2110
- Cancer Cell Int, 2020 19;20:58
- Cancer Cell Int, 2020 20:473
- Mol Cancer Ther, 2020 10.1158/1535-7163.MCT-19-0133
- Front Pharmacol, 2020 11:597520
- Front Pharmacol, 2020 10;11:252
- Cancers (Basel), 2020 30;12(5):E1118
- Aging (Albany NY), 2020 12(23):24424-24440
- Cancers (Basel), 2020 12(9)E2580
- Sci Rep, 2020 10(1):11574
- Sci Rep, 2020 10(1):13988
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Onco Targets Ther, 2020 13:1625-1635
- BMC Complement Med Ther, 2020 11;20(1):141
- BMC Cancer, 2020 20(1):31
- Ann Surg Oncol, 2020 10.1245/s10434-020-08790-2
- Photochem Photobiol, 2020 96(2):365-372
- Cancer Chemother Pharmacol, 2020 10.1007/s00280-020-04187-w
- Oncol Lett, 2020 19(1):663-670
- Exp Ther Med, 2020 20(2):1415-1422
- Mol Genet Genomic Med, 2020 e1409
- Anticancer Res, 2020 40(7):3659-3667
- Adv Sci (Weinh), 2019 6(21):1900667
- Biomaterials, 2019 222:119421
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-2409
- J Exp Clin Cancer Res, 2019 14;38(1):196
- Cancer Res, 2019 79(17):4491-4502
- Cell Death Dis, 2019 10(8):600
- Oncogene, 2019 10.1038/s41388-019-1004-2
- Cell Oncol (Dordr), 2019 10.1007/s13402-019-00471-x
- Int J Mol Sci, 2019
- J Mol Cell Biol, 2019 10.1093/jmcb/mjz032
- Biochim Biophys Acta Mol Cell Res, 2019 1866(10):1533-1543
- Chem Biol Interact, 2019 315:108886
- Hum Vaccin Immunother, 2019 10.1080/21645515.2019.1665960
- Front Oncol, 2019
- Sci Rep, 2019 9(1):16647
- Sci Rep, 2019 9(1):10845
- Cancer Med, 2019 10.1002/cam4.2764
- Neoplasma, 2019 66(1):39-45
- Oncol Lett, 2019 17(6):5023-5029
- Oncol Lett, 2019 5(3):935-942
- Nat Commun, 2018 9(1):2237
- Nat Commun, 2018 9(1):2434
- Theranostics, 2018 8(5): 1312–1326
- Elife, 2018 7e32838
- Oncoimmunology, 2018 7(5):e1424676
- Oncoimmunology, 2018 7(6):e1431086
- Cell Death Discov, 2018 4:116
- Oncotarget, 2018
- Oncotarget, 2018 9(45):27835-27850
- Int J Oncol, 2018 53(2):844-854
- Transl Oncol, 2018 11(6):1406-1418
- Toxicol Appl Pharmacol, 2018 356:159-171
- Acta Biochim Biophys Sin (Shanghai), 2018 50(4):370-380
- Cancer Chemother Pharmacol, 2018 81(2):255-267
- Sci Adv, 2018 4(9):eaar4666
- Proc Natl Acad Sci U S A, 2017 114(18):E3729-E3738
- Mol Cancer Res, 2017 15(1):15-25
- Sci Rep, 2017 7(1):10921
- Oncol Rep, 2017 38(4):2205-2210
- J Cancer, 2017 8(17):3555-3566
- SLAS Discov, 2017 22(5):507-515
- ACS Cent Sci, 2016 2(8):545-59
- Cancer Lett, 2016 380(1):87-97
- Cell Chem Biol, 2016 23(11):1428-1438
- Mol Cancer Ther, 2016 15(10):2302-2313
- Mol Pharm, 2016 13(11):3724-3735
- Biochem Biophys Res Commun, 2016 478(4):1772-9
- EMBO Mol Med, 2015 7(10):1350-65
- Oncotarget, 2015 6(31):31272-83
- Int J Cancer, 2014 136(4):E51-61
- Ann Surg Oncol, 2014 21(1):179-88
- J Biomed Opt, 2014 19(11):116001
- J Proteomics, 2014 113:326-36
- Cell Cycle, 2013 12(18):2960-8
- ACS Chem Biol, 2013 8(12):2771-7
- Optical Methods for Tumor Treatment and Detection, 2013 10.1117/12.2010730
化学信息&溶解度
分子量 | 397.29 |
分子式 | C8H14N2O4Pt |
CAS号 | 61825-94-3 |
Smiles | C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2] |
储存条件(自收到货起) | 2年 4°C(避光) 粉末 |
此产品性质不稳定,需现配现用!建议您购买分装规格,或者在收到货后进行分装。 |
体外溶解度 | 批次: |
Water : 5 mg/mL Ethanol : Insoluble Water : 1.5 mg/mL DMF : 1.25 mg/mL Ethanol : Insoluble Water : 7 mg/mL Ethanol : Insoluble Water : 3 mg/mL DMF : 2 mg/mL Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。